ISPACS’ Journal of Nonlinear Analysis and Application, whose website promises “very fast publication,” has pulled a paper for ripping off an article posted on arXiv.org. Their plagiarism wasn’t exactly subtle. Here’s the abstract from the paper on arXiv.org: We introduce and study the class of weak almost limited operators. We establish a characterization of pairs of Banach … Continue reading Math paper subtracted for plagiarism
The hits keep coming for University of Maryland researcher Anil Jaiswal. The latest retraction for the cell biologist is in Cancer Research, for a 2007 paper about ways in which the cell tries to protect the tumor suppressor p53. Like the first Jaiswal retraction we covered, the latest notice specifically taps figure duplication as the … Continue reading Fourth retraction appears for cancer researcher Anil Jaiswal
A PhD candidate in the law school of University of Malaya in Malaysia retracted a paper from a journal on Islamic law in governments, because he failed to add his deceased advisor as an author. The paper, which calls government secularism in Bangladesh “shadow rather than substance,” was published in Jurnal Syariah, which translates to Shariah Journal. It … Continue reading Law student retracts paper from journal of Shariah law
This week at Retraction Watch featured polar opposites: Two new entries in our “doing the right thing” category, and one in our plagiarism euphemism parade. Here’s what was happening elsewhere:
One of the papers from a massive heart disease study in China, published in the Lancet, has been retracted and republished after the authors noticed a statistical error. The article, by authors from Peking Union Medical College in China, Yale University, and elsewhere, presented the results of the China PEACE-Retrospective Acute Myocardial Infarction Study, part of … Continue reading Lancet retracts and republishes cardiology paper with admirable notice
Two papers by an overlapping group of researchers in Italy have been retracted for manipulated figures. In late 2013, perennial tipster Clare Francis sent their concerns about several papers, including the two that have been retracted, by authors who frequently publish together. One of the papers, in the Journal of Neurochemistry, is from a team led by Ferdinando Nicoletti; four other … Continue reading Cut and paste and a PC crash: figure manipulations sink two papers
A retracted 2008 paper originally flagged by Clare Francis has been republished in Environmental Health Perspectives with updated figures and new data. According to the editor’s note appended to the newly published paper, there was no evidence of intentional misconduct on the part of the authors. The new paper went through peer review as an entirely new submission, and comes … Continue reading Retracted paper on herbicide-ovarian cancer connection republished
We’re pleased to share this guest post from Leonid Schneider, a cell biologist, science journalist and a prolific cartoonist whose work graces our Twitter profile and Facebook page. In it, Schneider argues for a new way to ensure accountability for publicly funded research. It has become clear that scientific dishonesty is rarely sanctioned. In the worst case scenario, manipulated or … Continue reading What if universities had to agree to refund grants whenever there was a retraction?
A pair of cell biologists have taken responsibility for extensive figure errors that scuttled their paper in the Journal of Cell Biology. While there were five authors, first and last authors Eva Szabo and Michal Opas took responsibility in the notice. A number of figures “contain incorrect data and/or presentation errors,” and the original data isn’t available … Continue reading Fat cell paper earns unusually detailed retraction
A major scandal in Japan over the Novartis hypertension drug valsartan has resulted in a retraction from the Journal of Human Hypertension. Frequent Retraction Watch subject Hiroaki Matsubara resigned his post at Kyoto Prefectural University in 2013, after his work on valsartan was shown to be riddled with data errors and undisclosed conflicts of interest. Also that year, … Continue reading Can’t spell Novartis without VART: Drug study retracted for conflict of interest, data issues